Novel genes and markers in essential arterial hypertension

A test kit for risk assessment, molecular diagnosis or prognosis assessment of HT or a HT related condition from biological samples taken from mammalian subjects comprising:

• a) reagents, materials and protocols for assessing type and/or level of one or more HT associated biomarkers in a biological sample, wherein the biomarkers are related to one or more genes set forth in table 1, or said biomarkers are related to one or more polypeptides encoded by said genes, and;
• b) instructions and software for comparing the biomarker data from a subject to biomarker data from healthy and diseased people to make risk assessment, molecular diagnosis or prognosis of HT or a HT related condition.

Use of an agent modulating biological activity or function of a polypeptide encoded by a HT associated gene set forth in table 1 for manufacturing of a pharmaceutical composition for prevention or treatment of HT or a HT related condition in a mammalian subject

A method for preventing, treating or reducing the risk of HT or a HT related condition in a mammalian subject comprising a therapy modulating biological activity or function of a polypeptide encoded by a HT associated gene set forth in table 1.

A pharmaceutical composition for preventing, treating or reducing the risk of HT or a HT related condition in a mammalian subject comprising an agent modulating biological activity or function of a polypeptide encoded by a HT associated gene set forth in table 1.

A method for screening agents for preventing or treating HT or a HT related condition in a mammal comprising determining the effect of an agent either on a metabolic pathway related to a polypeptide or a RNA molecule encoded by a HT associated gene set forth in table 1 in living cells;

• wherein an agent altering activity of a metabolic pathway is considered useful in prevention or treatment of HT or a HT related condition.